Galmed Pharmaceuticals Ltd. Form 6-K April 04, 2019	
UNITED STATES	
SECURITIES AND EXCHANGE COMMISSION	
Washington, D.C. 20549	
FORM 6-K	
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16	
Under the Securities Exchange Act of 1934	
For the Month of April 2019	
001-36345	
(Commission File Number)	
GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter)	
16 Tiomkin St.	
Tel Aviv 6578317, Israel	
(Address of principal executive offices)	

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x	Form 40-F "
Indicate by che Rule 101(b)(1)	cck mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T:
Indicate by che	cck mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T:

Galmed Pharmaceuticals Ltd. (the "Company") announces that it will hold an Annual General Meeting of Shareholders on Monday, May 13, 2019 at 5:00 p.m. (Israel time) at the offices of the Company at 16 Tiomkin St., Tel Aviv, Israel. A copy of the Notice of the Annual General Meeting of Shareholders and Proxy Statement and the Proxy Card are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

This Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company's Registration Statement on Form F-3 (Registration No. 333-223923).

Exhibit Index

Exhibit No. Description

99.1 Notice of the Annual General Meeting of Shareholders and Proxy Statement

99.2 Proxy Card

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Galmed Pharmaceuticals Ltd.

Date: April 4, 2019 By: /s/ Allen Baharaff

Allen Baharaff

President and Chief Executive Officer